Veradermics to unveil Phase 2 female-arm data for oral minoxidil pill VDPHL01
The July 15 readout tests whether an extended-release oral minoxidil tablet can grow hair in women, feeding a Phase 3 program already running in men.
Executive Summary
- Veradermics is set to disclose female-arm results from an open-label Phase 2 trial of its oral extended-release minoxidil tablet, the first look at how the drug performs in women rather than men.
- The same drug already produced positive open-label results in men, and both a male and a female Phase 3 trial are already enrolling, so this readout functions as an interim data point inside a larger program rather than a standalone bet.
- The trial finished enrollment growth and shifted out of recruiting on schedule for its type, but it carries no placebo comparator, which limits what a single open-label result can establish on its own.
- Pattern hair loss has not had a new FDA-approved prescription drug in decades, and no rival oral non-hormonal androgen-receptor-targeted therapy has reached the same regulatory stage as VDPHL01's Phase 3 program.
The disclosure
Veradermics announced on July 14, 2026 that it will host a call and webcast the next morning to review results from the female arms of Study 207, an open-label Phase 2 trial of VDPHL01 registered as NCT06527365. The trial enrolled males and females with mild-to-moderate androgenetic alopecia and tracks change in non-vellus Total Area Hair Count as its stated outcome measure. VDPHL01 is described as a proprietary extended-release oral minoxidil tablet designed to sustain drug levels above the threshold needed for hair growth while avoiding the peak blood concentrations associated with immediate-release oral minoxidil. Veradermics+1Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair LossJul 14, 2026Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How the study was run
Study 207 is a single-arm, open-label Phase 2 trial with no placebo comparator, enrolling an anticipated 70 adult men and women. The trial started in July 2024, moved to Active, not recruiting status in September 2025, and lists a primary completion date of August 1, 2026. Its enrollment target rose from 20 to 70 participants, a 250% increase logged in a January 2025 registry update, and the primary completion date shifted twice, from August 2025 to February 2026 and then to August 2026, a cumulative 365-day delay. An enrollment increase of this size in a Phase 2 hair-loss trial before completion is consistent with expanding a cohort ahead of finalizing analysis, not evidence of an operational problem on its own. NCT06527365Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365
Same-drug precedent
VDPHL01 has already produced a same-drug data point: Veradermics reported positive open-label topline results from Part A of the separate Phase 2/3 Study 302 in men (NCT06724614) in April 2026, describing early, consistent hair growth and adverse-event rates comparable to placebo, without releasing numeric Month 6 primary endpoint data. That result sits alongside VDPHL01's active Phase 3 program: a male trial (NCT06972264, targeting 480 participants with a December 2026 completion) and a dedicated female Phase 3 trial (NCT07146022, targeting 552 participants with a June 2027 completion). The July 15 female Phase 2 data functions as an interim readout feeding that larger, placebo-controlled Phase 3 effort rather than a terminal result. NCT06527365Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365
The competitive landscape
Androgenetic alopecia has not seen a new FDA-approved prescription medicine in nearly three decades, according to Veradermics. Within androgen-receptor-directed programs specifically in this indication, the field includes Cassiopea SpA's clascoterone in Phase 3 for male pattern hair loss and Suzhou Kintor Pharmaceutical's KX-826 in Phase 2/3 for androgenetic alopecia, both direct comparators on target and modality. VDPHL01 differs from those programs by mechanism: it works through minoxidil's vasodilatory pathway rather than direct androgen-receptor antagonism, and by route, it is delivered as an oral extended-release tablet rather than a topical formulation, an approach the company says is intended to sustain drug exposure above the hair-growth threshold without the cardiac-risk concerns tied to immediate-release oral minoxidil. Among Phase 2 trials pairing the androgen-receptor target with this indication, four have completed and none have terminated, though that base rate spans a small, heterogeneous set of programs and mechanisms, not a direct read on VDPHL01 itself. Veradermics+1Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair LossJul 14, 2026Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.